Open the prescribing information for any GLP-1 medicine and you will find a section numbered 8.5, titled Geriatric Use. It is one of the shortest sections in the document, and across the class it says roughly the same thing: the trials did not show an overall difference between older and younger adults, and no different dose is recommended on the basis of age alone.
That is a reassuring pair of sentences, and it is also a thinner pair than it looks, because it rests on trials in which very few of the oldest old took part. This article reads the age sections of these labels, counts who was in the rooms when the medicines were studied, and looks at the ordinary effects of the class that deserve extra attention when someone is 70 or 80. It is label reading plus a set of things worth watching. Whether any older adult should take one of these medicines is a question for that person and their clinician, and nothing here weighs in on it.
What the labels say about age
Every GLP-1 label carries the Geriatric Use section, and none of them sets a different dose for older adults. The labels also decline to adjust dosing for kidney function: Ozempic, Zepbound and Mounjaro each state that no dosage adjustment is recommended in patients with renal impairment. Age alone does not change the dose the label describes, and neither does the kidney situation of the person taking it, as far as the label is concerned.
The conclusions differ only in wording. The Wegovy label reports no overall difference in effectiveness between patients aged 65 and older and younger adults. The Zepbound and Mounjaro labels report no overall differences in safety or effectiveness between patients 65 and older and younger adults. The Ozempic label says no overall differences in safety or efficacy were detected, and then adds a clause worth keeping: greater sensitivity of some older individuals cannot be ruled out. That is standard label language, and it is also the honest caveat underneath every short Geriatric Use section. What can be detected is limited by who was studied.
How many of the oldest were in the rooms
The numbers behind those sentences deserve a direct look. In the Wegovy weight reduction trials, 233 patients, 9 percent, were aged 65 to under 75, and 23 patients, 1 percent, were aged 75 and older. The two fixed dose Zepbound weight studies included 226 patients aged 65 or older, 9 percent, and 13 patients aged 75 or older, 0.5 percent. The Zepbound label adds that the sleep apnea studies did not include sufficient numbers of patients 65 or older to determine whether they respond differently.
The outcome trials, which enrolled older populations by design, look different. Wegovy's cardiovascular outcomes trial included 2,656 patients aged 65 to 75, 30 percent, and 703 aged 75 and older, 8 percent. In Ozempic's pooled glycemic control trials, 744 patients, 23.6 percent, were 65 and over and 102, 3.2 percent, were 75 and over, while its SUSTAIN 6 cardiovascular trial enrolled higher proportions: 788 patients, 48 percent, at 65 and over, and 157, 9.6 percent, at 75 and over. Mounjaro's pool of seven clinical trials included 1,539 patients aged 65 or older, 30.1 percent, and 212 aged 75 or older, 4.1 percent, and its cardiovascular outcomes trial included 3,327 patients aged 65 or older, 50 percent, and 705 aged 75 or older, 11 percent. And in the Wegovy MASH trial, 138 of the 534 patients randomized to Wegovy, 26 percent, were 65 and older, and 13, 2 percent, were 75 and older, with no overall differences in safety or effectiveness observed by age in that trial.
Read together, these are two different evidence bases. For people in their late 60s and early 70s there is a real body of trial data, and it points to no overall difference by age. Past 75, the weight trials studied a few dozen people at most. The honest summary is not that the medicines are dangerous after 75; it is that the trials cannot answer questions about the oldest old with much precision, and that is exactly the kind of uncertainty a prescriber weighs when treating someone in that age group.
The one age specific signal on any of these labels
A single age related finding appears anywhere in the class, in the Geriatric Use section of the Wegovy label, and it deserves to be reported completely rather than in a headline. In the cardiovascular outcomes trial, patients aged 75 years and older reported more hip and pelvis fractures in the Wegovy treated patients than placebo treated patients. The very next sentence matters as much as the first: patients aged 75 years and older, in both the Wegovy treated and the placebo treated groups, reported more serious adverse reactions overall compared to younger adult patients.
Three things belong in any honest reading. It is an imbalance reported in one trial's oldest subgroup. The label does not claim the medicine caused the fractures, and no rate or risk ratio is given to attach to it. And the second sentence shows that the oldest patients had more serious events of every kind in both arms, which is partly what being 75 plus in a cardiovascular outcomes trial looks like. Nothing about this is a reason for any reader to change anything on their own. It is a reason the subject belongs in the conversation an 80 year old and their clinician have, ideally before anything is prescribed.
GLP 1 Tracker AppDated doses, side effect notes and a weight trend in one private place: the record a clinician actually wants to see, whether you keep it or a family member keeps it with your consent.
Get the app
Muscle and appetite: a smaller margin
Two ordinary effects of this class deserve extra attention as age rises. The first is lean mass. Muscle declines naturally over the years, and rapid weight loss costs lean tissue when protein intake and resistance training do not hold the line. The commonly cited guidance for people on GLP-1s, roughly 1.0 to 1.5 grams of protein per kilogram of body weight daily alongside regular resistance work, exists for exactly this reason, and the two subjects have practical guides in Protein Goals on GLP-1s: Protecting Muscle While Losing Weight and Two Days of Strength Training: The GLP-1 Muscle Insurance. What any individual should do about protein or exercise is a question for their clinician or a dietitian who can see their history. Nothing here is a program.
The second is appetite itself. A quieter appetite is the point of the medicine, and it is a larger problem when someone was already eating little before the first dose. Falling short on protein and fluid is easier at 78 than at 38, because the appetite that would normally correct a shortfall has been turned down. Family members who share meals often notice this before anyone reports it, which is one reason involving them, with consent, is worth considering.
Fluids, kidneys and the other pills
Every label in the class carries a warning about acute kidney injury related to volume depletion from gastrointestinal losses, meaning the fluid lost through vomiting or diarrhea. Dehydration is the mechanism to respect, and age makes it easier to fall into, partly because thirst cues blunt on these medicines and partly because they blunt on their own with age. The wider story sits in GLP-1s and Your Kidneys: Why Dehydration Is the Risk, and the practical side of replacing more than water is covered in Electrolytes on a GLP-1: When Water Alone Is Not Enough.
The other interaction is mechanical rather than chemical. Slowed gastric emptying changes when oral medicines are absorbed, and the number of oral medicines a person takes tends to grow over the years. The labels tell prescribers what to weigh for medicines taken by mouth alongside these drugs, and what any of that means for a specific pillbox belongs to the prescriber and the pharmacist, full stop. The subject has its own overview in GLP-1s and Your Other Pills: What the Labels Say About Timing, and no reader should move a medicine's schedule on the strength of an article.
Where the family fits
Much of what makes treatment go well at an older age is the same as at any age: doses taken as prescribed, effects noted, weight and appetite trends visible at appointments. What changes is who does the noticing. An adult child or partner who has been asked to help can keep the log on someone's behalf, with their consent, and the mechanics of doing that respectfully are the whole subject of Tracking a Family Member’s GLP-1 Journey, With Consent.
The summary can be short. The labels set no special dose after 65 and report no overall difference by age, on evidence that includes far fewer people past 75 than under it. One trial reported more hip and pelvis fractures in its oldest subgroup, without claiming a cause, alongside more serious events in both arms at those ages. And the class's ordinary demands, protein, fluids and attention to the rest of the pillbox, land on a body with less reserve than it had at 40. All of it is manageable, and none of it is a do it yourself project.
Frequently asked questions
Is there a different GLP-1 dose for people over 65?
No. Every GLP-1 label carries a Geriatric Use section, and none of them sets a different dose for older adults. The Ozempic, Zepbound and Mounjaro labels also state that no dosage adjustment is recommended in patients with renal impairment. Any change to how a dose is taken belongs to the prescriber, who can see the full medication list and the kidney history behind the question.
Were people over 75 included in the GLP-1 trials?
Some were, but very few in the weight loss studies. The Wegovy weight trials included 23 patients aged 75 and older, 1 percent of the total, and the Zepbound weight studies included 13, 0.5 percent. The cardiovascular outcomes trials enrolled more: 703 people aged 75 and older in the Wegovy trial and 705 in the Mounjaro trial. The oldest group is simply studied far less than everyone else.
Should an older adult stop a GLP-1 because of the fracture finding?
No, and no article should be the reason. The finding is an imbalance reported in one cardiovascular outcomes trial subgroup aged 75 and older, in which Wegovy treated patients reported more hip and pelvis fractures than placebo patients, and the label does not claim the medicine caused it. The same section reports more serious adverse reactions in that age group in both arms. It is a subject for the prescriber, not a decision to make alone.
Are GLP-1s harder on the kidneys in older adults?
The labels set no dose change for age or for renal impairment, but all of them warn about acute kidney injury related to volume depletion from gastrointestinal losses such as vomiting or diarrhea. Falling behind on fluids is easier when thirst cues are blunted, which happens on these medicines and with age itself. Fluids deserve real attention, and any concern about kidney function belongs with a clinician.
Does weight loss on a GLP-1 cost more muscle after 65?
Lean mass is a concern at any age on these medicines, and the margin narrows with age because muscle naturally declines over the years. Commonly cited guidance for GLP-1 users points to adequate daily protein, roughly 1.0 to 1.5 grams per kilogram of body weight, alongside resistance training, with the details set by a clinician or dietitian. Strength work and protein are the parts of the plan that protect muscle.